Bio-X
Showing 1,081-1,100 of 1,149 Results
-
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines. -
Kenneth Weber, DC, PhD
Assistant Professor (Research) of Anesthesiology, Perioperative and Pain Medicine (Adult Pain) and, by courtesy, of Neurosurgery (Adult Neurosurgery) and of Radiology (Neuroimaging and Neurointervention)
BioDr. Weber directs the Neuromuscular Insight Lab. Dr. Weber's research seeks to develop quantitative markers of sensory and motor function, including pain, using machine-learning and advanced brain, spinal cord, and musculoskeletal magnetic resonance imaging. Dr. Weber aims to use these techniques to better understand the neuropathology of neurological and musculoskeletal conditions and discover more effective treatments and preventative strategies.
-
Katja Gabriele Weinacht, MD, PhD
Assistant Professor of Pediatrics (Stem Cell Transplantation and Regenerative Medicine)
Current Research and Scholarly InterestsPediatric Hematopoietic Stem Cell Transplantation
DiGeorge Syndrome
Genetic Immune Diseases
Immune Dysregulation -
Irving Weissman
Virginia & D.K. Ludwig Professor of Clinical Investigation in Cancer Research, Professor of Pathology, and of Developmental Biology
Current Research and Scholarly InterestsStem cell and cancer stem cell biology; development of T and B lymphocytes; cell-surface receptors for oncornaviruses in leukemia. Hematopoietic stem cells; Lymphocyte homing, lymphoma invasiveness and metastasis; order of events from hematopoietic stem cells [HSC] to AML leukemia stem cells and blood diseases, and parallels in other tissues; discovery of tumor and pathogenic cell 'don't eat me' and 'eat me' signals, and translation into therapeutics.
-
Itschak Weissman
Robert and Barbara Kleist Professor in the School of Engineering
BioTsachy's research focuses on Information Theory, Data Compression and Communications, Statistical Signal Processing, Machine Learning, the interplay between them, and their applications, with recent focus on applications to genomic data compression and processing. He is inventor of several patents and involved in several companies as member of the technical board. IEEE fellow, he serves on the board of governors of the information theory society as well as the editorial boards of the Transactions on Information Theory and Foundations and Trends in Communications and Information Theory. He is founding Director of the Stanford Compression Forum.
-
Paula V. Welander
Associate Dean for Research and Professor of Earth System Science
Current Research and Scholarly InterestsBiosynthesis of lipid biomarkers in modern microbes; molecular geomicrobiology; microbial physiology
-
Paul Wender
Francis W. Bergstrom Professor and Professor, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsMolecular imaging, therapeutics, drug delivery, drug mode of action, synthesis
-
Gerlinde Wernig
Associate Professor of Pathology
Current Research and Scholarly InterestsFibrotic diseases kill more people than cancer in this country and worldwide. We believe that scar-forming cells called fibroblasts are at the core of the fibrotic response in parenchymal organ fibrosis in the lung, liver, skin, bone marrow and tumor stroma. At the cellular level we think of fibrosis as a step wise process which implicates inflammation and fibrosis. We seek to identify new effective immune therapy targets to treat fibrotic diseases.
-
Marius Wernig
Professor of Pathology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsEpigenetic Reprogramming, Direct conversion of fibroblasts into neurons, Pluripotent Stem Cells, Neural Differentiation: implications in development and regenerative medicine
-
Robert West
Sabine Kohler, MD, Professor of Pathology
Current Research and Scholarly InterestsRob West, MD, PhD, is a Professor of Pathology at Stanford University Medical Center. He is a clinician scientist with experience in translational genomics research to identify new prognostic and therapeutic markers in cancer. His research focus is on the progression of neoplasia to carcinoma. His lab has developed spatially oriented in situ methods to study archival specimens. He also serves as a surgical pathologist specializing in breast pathology.
-
Lynn Marie Westphal, M.D.
Professor of Obstetrics and Gynecology (Reproductive Endocrinology and Infertility) at Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsInfertility, fertility preservation, oocyte cryopreservation
-
Gordon Wetzstein
Associate Professor of Electrical Engineering and, by courtesy, of Computer Science
BioGordon Wetzstein is an Associate Professor of Electrical Engineering and, by courtesy, of Computer Science at Stanford University. He is the leader of the Stanford Computational Imaging Lab and a faculty co-director of the Stanford Center for Image Systems Engineering. At the intersection of computer graphics and vision, artificial intelligence, computational optics, and applied vision science, Prof. Wetzstein's research has a wide range of applications in next-generation imaging, wearable computing, and neural rendering systems. Prof. Wetzstein is a Fellow of Optica and the recipient of numerous awards, including an NSF CAREER Award, an Alfred P. Sloan Fellowship, an ACM SIGGRAPH Significant New Researcher Award, a Presidential Early Career Award for Scientists and Engineers (PECASE), an SPIE Early Career Achievement Award, an Electronic Imaging Scientist of the Year Award, an Alain Fournier Ph.D. Dissertation Award as well as many Best Paper and Demo Awards.
-
Cornelia Weyand
Professor of Medicine (Immunology and Rheumatology), Emerita
Current Research and Scholarly InterestsAutoimmunity
Chronic inflammatory disease
Metabolic control of immune function -
Matthew T. Wheeler
Associate Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsTranslational research in rare and undiagnosed diseases. Basic and clinical research in cardiomyopathy genetics, mechanisms, screening, and treatment. Investigating novel agents for treatment of hypertrophic cardiomyopathy and new mechanisms in heart failure. Cardiovascular screening and genetics in competitive athletes, disease gene discovery in cardiomyopathy and rare disease. Informatics approaches to rare disease and multiomics. Molecular transducers of physical activity bioinformatics.
-
Francis Robert Willett
Assistant Professor of Neurosurgery
BioFrank Willett is co-director of the Neural Prosthetics Translational Laboratory. Our group develops brain-computer interfaces (BCIs) to restore movement and communication to people with neurological disorders. Recent contributions include handwriting and speech-based BCIs that set new records for communication speed and accuracy in people with paralysis. More broadly, we are interested in computational approaches to understanding brain function and recordings, with a focus on how the human brain represents movement and language.
-
Leanne Williams
Vincent V.C. Woo Professor and Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical Translational Neurosciences Incubator)
Current Research and Scholarly InterestsA revolution is under way in psychiatry. We can now understand mental illness as an expression of underlying brain circuit disruptions, shaped by experience and genetics. Our lab is defining precision brain circuit biotypes for depression, anxiety and related disorders. We integrate large amounts of brain imaging, behavioral and clinical data and computational approaches. Biotypes are used in personalized intervention studies with selective drugs, neuromodulation and exploratory therapeutics.
-
Michelle Williams, ScD
Professor of Epidemiology and Population Health
BioMichelle A. Williams, ScD, is Professor of Epidemiology and Population Health and Associate Chair for Academic Affairs in the Department of Epidemiology and Population Health at Stanford University, School of Medicine.
Dr. Williams' research focuses primarily on reproductive and perinatal epidemiology. Over three decades, she has integrated epidemiological, biological, and molecular approaches into rigorously designed research that has advanced understanding of placental abruption, gestational diabetes, and preeclampsia. Her research methodology includes: (1) identifying literature gaps; (2) developing robust epidemiological data systems across North America, Sub-Saharan Africa, Asia, and South America; and (3) integrating biochemical and molecular biomarkers into these platforms. She has effectively utilized various epidemiology study designs to investigate adverse reproductive and perinatal outcomes. Her consistent goal has been using biological and molecular biomarkers as objective measures of exposures and validated pre-clinical determinants of outcomes with clinical and global health significance. In 2019, in partnership with Apple Inc. and the National Institute of Environmental Health Sciences, she co-designed and currently co-leads the Apple Women's Health Study, a large-scale digital national study examining determinants of women's gynecological health.
Dr. Williams has advanced knowledge of understudied gynecological, obstetric, and perinatal outcomes while identifying novel risk factors. Her research has been funded by multiple NIH R01s, R03s, an SBIR, and HRSA grants, and she has served as co-investigator on numerous other grants. She has published over 540 peer-reviewed scientific articles and was elected to the National Academy of Medicine in 2016. In 2020, she received the Ellis Island Medal of Honor and was recognized by PR Week as one of the top 50 health influencers of the year.
Dr. Williams has been recognized for her excellence in teaching, as the recipient of the 2015 Harvard Chan School’s Outstanding Mentor Award, the UW’s Brotman Award for excellence in teaching (2007), the American Public Health Association’s Abraham Lilienfeld Award for education in epidemiology (2007), and the White House’s Presidential Award for Excellence in Science, Mathematics, and Engineering Mentoring (2012).
Before joining Stanford, Dr. Williams served as Dean of the Faculty at the Harvard T.H. Chan School of Public Health. Prior to her deanship, she was Professor and Chair of the Department of Epidemiology at Harvard Chan School and Program Leader of Population Health and Health Disparities Research Programs at Harvard's Clinical and Translational Sciences Center.
Dr. Williams previously had a distinguished career at the University of Washington School of Public Health. She holds an undergraduate degree in biology and genetics from Princeton University, a master's in civil engineering from Tufts University, and master's and doctoral degrees in epidemiology from the Harvard Chan School. -
Nolan Williams
Professor of Psychiatry and Behavioral Sciences (Major Laboratories & Clinical Translational Neurosciences Incubator)
BioNolan Williams, M.D. is a Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. The long-term goals of his research program are to develop innovative technologies and therapeutics capable of modulating the neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions. His team has been developing neuroimaging-based approaches to precisely target therapeutic delivery and predict treatment responses to therapeutic neuromodulation and psychedelics. Dr. Williams earned his M.D. and completed his dual residencies in neurology and psychiatry at the Medical University of South Carolina (MUSC). Triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry, Dr. Williams brings a comprehensive background in clinical neuroscience to his role as a clinically active neuropsychiatrist. His expertise extends to the development and implementation of novel therapeutics, including devices and novel compounds, for central nervous system illnesses.
Over the past decade, Dr. Williams’ laboratory alongside collaborators at Stanford University have pioneered multiple novel therapeutic and human neuroscience approaches. Notably, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) is the world's first non-invasive, rapid-acting neuromodulation approach for treatment-resistant depression. SAINT received FDA Breakthrough Device Designation Status (2021) and FDA Clearance (2022) and is the first psychiatric treatment to be covered by Medicare New Technology Add-On Payment (NTAP). As of April 2024, SAINT has been reimbursed for patients suffering from severe depression within inpatient psychiatric units. The SAINT technology is being deployed both clinically and in research protocols in laboratories and hospitals worldwide. Dr. Williams also has an expertise in psychedelic medicines for neuropsychiatric illness and is the first investigator to conduct mechanistic clinical trials exploring the neurobiological effects of ibogaine.
His research accomplishments have garnered international recognition, earning prestigious awards from the Pritzker Neuropsychiatric Disorders Consortium, One Mind Institute, Wellcome Leap Foundation, International Brain Stimulation Conference, National Institute of Mental Health (Biobehavioral Research Award for Innovative New Scientists), Society of Biological Psychiatry (A. E. Bennett Award), along with multiple awards from the Brain Behavior Research Foundation (most notably the Gerald L. Klerman Award and Colvin Prize). His work has been featured in Scientific American, The New York Times, The Washington Post, USA Today, CBS Sunday Morning, and the TODAY Show. -
Darrell Wilson
Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsMy research interests cover a number of areas in Pediatric Endocrinology and Diabetes. I am PI of the Stanford Center for the NIH-funded Type-1 Diabetes TrialNet group. TrialNet conducts clinical trials directed at preventing or delaying the onset of Type 1 diabetes. I am an investigator in DirecNet, another NIH-funded study group, which is devoted to evaluating glucose sensors and the role of technology on the management of diabetes.
